Combination therapy for skin disorders

Abstract

The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.

1 .- 12 . (canceled) 
     
     
         13 . A method of alleviating acne in a patient in need thereof, the method comprising simultaneously or sequentially administering, to the patient, a therapeutically effective amount of 4′,7-isoflavandiol or a pharmaceutically acceptable salt or hydrate thereof and minocycline or a pharmaceutically acceptable salt or hydrate thereof. 
     
     
         14 . The method of  claim 13 , wherein the 4′,7-isoflavandiol or the pharmaceutically acceptable salt or hydrate thereof and the minocycline or the pharmaceutically acceptable salt or hydrate thereof are administered simultaneously as a single dosage unit. 
     
     
         15 . The method of  claim 13 , wherein the 4′,7-isoflavandiol or the pharmaceutically acceptable salt or hydrate thereof and the minocycline or the pharmaceutically acceptable salt or hydrate thereof are administered as separate compositions simultaneously or sequentially. 
     
     
         16 . The method of  claim 13 , wherein the single dosage unit is formulated for oral administration. 
     
     
         17 . The method of  claim 15 , wherein the separate compositions are formulated for oral administration. 
     
     
         18 . The method of  claim 13 , wherein the 4′,7-isoflavandiol or the pharmaceutically acceptable salt or hydrate thereof is present in a racemic mixture. 
     
     
         19 . The method of  claim 13 , wherein the 4′,7-isoflavandiol or the pharmaceutically acceptable salt or hydrate thereof is present in the “S-” form. 
     
     
         20 . The method of  claim 13 , wherein the method further comprises administering an oral contraceptive, an estrogen analog, a progesterone analog, spironolactone, inocoterone acetate, cyproterone acetate, flutamide, nilutamide, bicalutamide, keto-conazole, finasteride, dutasteride, bexlosteride, izonsteride, epresteride, turosteride, isoflavanoid, RU-58642, RU-56279, WS9761 A and B, RU-59063, RU-58841, bexlosteride, LG-2293, L-245976, LG-121071, LG-121091, LG-121104, LGD-2226, LGD-2941, YM-92088, YM-175735, LGD-1331, LGD-3303, BMS-357597, S-40503, BMS-482404, EM-4283, EM-4977, BMS-564929, BMS-391197, BMS-434588, BMS-487745, BMS-501949, SA-766, YM-92088, YM-580, LG-123303, LG-123129, PMCol, YM-175735, BMS-591305, BMS-591309, BMS-665139, BMS-665539, CE 590, 116BG33, 154BG31, arcarine, ACP-105, flutamide, hydroxyflutamide, bicalutamide, nilutamide, a hydroxy-steroid dehydrogenase inhibitor, a PPARα ligand, a dual acting PPAR ligand, PN-2034, PPAR δ, a 17-ketoreductase inhibitor, a 3β-DHΔ4,6-isomerase inhibitor, a 3β-DHΔ4,5-isomerase inhibitor, a 17,20 desmolase inhibitor, a p450c17 inhibitor, a_p450ssc inhibitor, and a 17,20-lyase inhibitor. 
     
     
         21 . The method of  claim 13 , wherein the acne is acne vulgaris or acne rosacea. 
     
     
         22 . The method of  claim 14 , wherein the single dosage unit is formulated for topical administration. 
     
     
         23 . The method of  claim 15 , wherein the separate compositions are formulated for topical administration.